VN March 2021

Vetnews | March 2021 7 The safety assessment relates to the undesired, adverse effects, and whether they are proportional to the proposed use. For example, a treatment for a severe and potentially fatal disease may be associated with serious adverse effects. But, on balance they may be considered acceptable. On the basis of safety considerations, medicines can be restricted to prescription-only access, or pharmacist-initiated sale, or placed on the market for general sale. In some cases, a formal post-registration obligation is placed on the applicant. Examples include research on use in children. But most post-registration safety data comes from spontaneous reporting by health professionals and patients. Anything reported to the manufacturer must be reported to the regulator. Efficacy data describe whether the medicine achieves its proposed purpose in preventing or treating a disease or symptom. The data also shows whether there are important differences in effect between patient groups. For example, it is affected by age or gender. Importantly, there are certain things the regulator is excluded from factoring in. These include: • the price of a medicine • its cost-effectiveness to the health system, or • its affordability. This responsibility lies with the Minister of Health and a pricing committee. The process In the case of medicines and vaccines, the starting point for the regulator’s assessment is the dossier submitted by the applicant. This is a comprehensive and exhaustive submission of the evidence of quality, safety and efficacy. After initial screening, the elements of the common technical document are referred to specific evaluators. These are often external people, or technical advisory committee members. Their assessments, after peer review and sometimes committee deliberations, inform the eventual regulatory decisions. The final decision to issue a certificate of marketing authorisation is accompanied by: • specific conditions, • approval of the professional information and patient information leaflets, and • an approved proprietary (brand) name for the product. Lastly, each batch of biological medicines, such as vaccines, is tested at the National Control Laboratory for Biological Products. The University of the Free State-based National Control Laboratory for Biological Products (NCL) is a full member of the international WHO-National Control Laboratory Network for Biologicals and one of 12 laboratories worldwide contracted to perform vaccine testing for the World Health Organisation (WHO). The NCL is also the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of the South African Health Products Regulatory Authority (SAHPRA). Many of the assessments conducted by the South African regulator mayhavebeendonebyone inanother country.Toavoidduplication, and speed up decision-making, regulators engage in what is called “reliance”. They enter into agreements to share information and co- operate in making regulatory decisions. In a minority of applications, South Africa’s regulator can “rely” on prior decisions taken by well-resourced and mature regulators, and focus its efforts only on issues that are specific to circumstances in the country. The South African Health Products Regulatory Authority’s response to COVID-19 has been questioned. Advocates for medicines that are unregistered in South Africa have accused the body of not being proactive in bringing such products to market and approving their use. But an applicant is needed to provide a quality–assured product and to be held accountable for meeting those standards. The authority can’t approve a product in the absence of an appropriate applicant. The body has also been criticised for not conducting the necessary clinical trials to provide the needed evidence of safety and efficacy. Again, its role is to regulate such trials, not to conduct or fund them. Meeting mandates National medicines regulatory authorities are gatekeepers that protect the public from unnecessary harm from health products. They do so in the best tradition of the injunction to “do no harm”. Leading Article >>> 8

RkJQdWJsaXNoZXIy OTc5MDU=